Vaxart

Vaxart, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, specializing in the discovery and development of oral recombinant protein vaccines using its proprietary vaccine platform. The company is focused on creating oral vaccines that can generate broad and durable immune responses against various infectious diseases. Its product pipeline includes an oral tablet vaccine for norovirus, which has completed Phase I clinical trials, a seasonal influenza vaccine currently in Phase II trials, and vaccines targeting respiratory syncytial virus and coronavirus. Additionally, Vaxart is developing therapeutic vaccines for human papillomavirus-related conditions. The company aims to improve vaccination rates by offering a convenient, room temperature-stable tablet format, which is easier to distribute and administer compared to traditional injectable vaccines. Vaxart also has a research collaboration with Janssen Vaccines & Prevention B.V. to explore its oral vaccine platform for a universal influenza vaccine program.

Phillip Lee

CFO

1 past transactions

Aviragen Therapeutics

Acquisition in 2017
Aviragen Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery and development of innovative therapies for serious infectious diseases. The company is advancing two Phase 2 clinical-stage candidates: laninamivir octanoate for the treatment of influenza A and B infections, supported by a substantial contract with the U.S. Office of Biomedical Advanced Research and Development Authority, and vapendavir, an oral broad-spectrum capsid inhibitor targeting enteroviruses, particularly human rhinovirus. Additionally, Aviragen is engaged in preclinical programs aimed at developing treatments for respiratory syncytial virus (RSV) and is exploring oral therapies for human rhinovirus infections in patients with moderate-to-severe asthma, as well as topical antiviral treatments for conditions caused by human papillomavirus.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.